314 related articles for article (PubMed ID: 24891295)
1. CD30-positive lymphoproliferative disorders arising after regional therapy for recurrent melanoma: a report of two cases and analysis of CD30 expression.
Gill K; Ariyan C; Wang X; Brady MS; Pulitzer M
J Surg Oncol; 2014 Sep; 110(3):258-64. PubMed ID: 24891295
[TBL] [Abstract][Full Text] [Related]
2. MUM1 expression in cutaneous CD30+ lymphoproliferative disorders: a valuable tool for the distinction between lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma.
Kempf W; Kutzner H; Cozzio A; Sander CA; Pfaltz MC; Müller B; Pfaltz M
Br J Dermatol; 2008 Jun; 158(6):1280-7. PubMed ID: 18410414
[TBL] [Abstract][Full Text] [Related]
3. CD30
Sauder MB; O'Malley JT; LeBoeuf NR
Hematol Oncol Clin North Am; 2017 Apr; 31(2):317-334. PubMed ID: 28340881
[TBL] [Abstract][Full Text] [Related]
4. Primary cutaneous CD30 positive T-cell lymphoproliferative disorders with aberrant expression of PAX5: report of three cases.
Hagiwara M; Tomita A; Takata K; Shimoyama Y; Yoshino T; Tomita Y; Nakamura S
Pathol Int; 2012 Apr; 62(4):264-70. PubMed ID: 22449230
[TBL] [Abstract][Full Text] [Related]
5. Loss of expression of 5-hydroxymethylcytosine in CD30-positive cutaneous lymphoproliferative disorders.
De Souza A; Tinguely M; Pfaltz M; Burghart DR; Kempf W
J Cutan Pathol; 2014 Dec; 41(12):901-6. PubMed ID: 25353265
[TBL] [Abstract][Full Text] [Related]
6. Expression of CD44 and CD44v6 in primary cutaneous CD30 positive T-cell lymphoproliferative disorders.
Liang X; Smoller BR; Golitz LE
J Cutan Pathol; 2002 Sep; 29(8):459-64. PubMed ID: 12207739
[TBL] [Abstract][Full Text] [Related]
7. Primary cutaneous CD30+ lymphoproliferative disorders: new insights into biology and therapy.
Querfeld C; Kuzel TM; Guitart J; Rosen ST
Oncology (Williston Park); 2007 May; 21(6):689-96; discussion 699-700,. PubMed ID: 17564326
[TBL] [Abstract][Full Text] [Related]
8. Contribution of longitudinal follow up and clinical pathological correlation in the diagnosis CD30-positive skin infiltrates.
De Souza A; Carter JB; Harris NL; Ferry JA; Duncan LM
J Cutan Pathol; 2015 Jul; 42(7):452-8. PubMed ID: 25931140
[TBL] [Abstract][Full Text] [Related]
9. A new era for cutaneous CD30-positive T-cell lymphoproliferative disorders.
Kempf W
Semin Diagn Pathol; 2017 Jan; 34(1):22-35. PubMed ID: 27993440
[TBL] [Abstract][Full Text] [Related]
10. Primary cutaneous CD30+ lymphoproliferative disorder--a 10-year follow-up. A case report and differential diagnosis.
Szpor J; Dyduch G; Gałazka K; Bahyrycz J; Stój A; Tomaszewska R
Pol J Pathol; 2009; 60(1):43-8. PubMed ID: 19670703
[TBL] [Abstract][Full Text] [Related]
11. CD30-Positive Lymphoproliferative Disorders.
Nikolaenko L; Zain J; Rosen ST; Querfeld C
Cancer Treat Res; 2019; 176():249-268. PubMed ID: 30596222
[TBL] [Abstract][Full Text] [Related]
12. Death receptor apoptosis signaling mediated by FADD in CD30-positive lymphoproliferative disorders involving the skin.
Clarke LE; Bayerl MG; Bruggeman RD; Mauger D; Ioffreda MD; Abou-Elella A; Helm KF
Am J Surg Pathol; 2005 Apr; 29(4):452-9. PubMed ID: 15767797
[TBL] [Abstract][Full Text] [Related]
13. Novel use of 308-nm excimer laser to treat a primary cutaneous CD30+ lymphoproliferative nodule.
Meisenheimer JL
J Drugs Dermatol; 2007 Apr; 6(4):440-2. PubMed ID: 17668543
[TBL] [Abstract][Full Text] [Related]
14. CD30+ lymphoproliferative disorder with spindle-cell morphology.
Martires KJ; Cohen BE; Cassarino DS
J Cutan Pathol; 2016 Nov; 43(11):1041-1044. PubMed ID: 27433975
[TBL] [Abstract][Full Text] [Related]
15. Regional hyperthermic perfusion with melphalan after surgery for recurrent malignant melanoma of the extremities--long-term follow-up of a randomised trial.
Olofsson Bagge R; Mattsson J; Hafström L
Int J Hyperthermia; 2014 Aug; 30(5):295-8. PubMed ID: 25144818
[TBL] [Abstract][Full Text] [Related]
16. Pityriasis lichenoides et varioliformis acuta with numerous CD30(+) cells: a variant mimicking lymphomatoid papulosis and other cutaneous lymphomas. A clinicopathologic, immunohistochemical, and molecular biological study of 13 cases.
Kempf W; Kazakov DV; Palmedo G; Fraitag S; Schaerer L; Kutzner H
Am J Surg Pathol; 2012 Jul; 36(7):1021-9. PubMed ID: 22472952
[TBL] [Abstract][Full Text] [Related]
17. Repeat isolated limb perfusion with TNFalpha and melphalan for recurrent limb melanoma after failure of previous perfusion.
Noorda EM; Vrouenraets BC; Nieweg OE; van Geel AN; Eggermont AM; Kroon BB
Eur J Surg Oncol; 2006 Apr; 32(3):318-24. PubMed ID: 16412605
[TBL] [Abstract][Full Text] [Related]
18. The differential diagnosis of CD8-positive ("type D") lymphomatoid papulosis.
McQuitty E; Curry JL; Tetzlaff MT; Prieto VG; Duvic M; Torres-Cabala C
J Cutan Pathol; 2014 Feb; 41(2):88-100. PubMed ID: 24118002
[TBL] [Abstract][Full Text] [Related]
19. Potential involvement of Notch1 signalling in the pathogenesis of primary cutaneous CD30-positive lymphoproliferative disorders.
Kamstrup MR; Ralfkiaer E; Skovgaard GL; Gniadecki R
Br J Dermatol; 2008 Apr; 158(4):747-53. PubMed ID: 18241263
[TBL] [Abstract][Full Text] [Related]
20. Recurrent course and CD30 expression of atypical T lymphocytes distinguish lymphomatoid papulosis from primary cutaneous aggressive epidermotropic CD8+ cytotoxic T-cell lymphoma.
Tsujiwaki M; Abe R; Ohguchi Y; Hoshina D; Murata J; Fujita Y; Nomura T; Ambo M; Shimizu H
Acta Derm Venereol; 2014 Sep; 94(5):613-4. PubMed ID: 24549273
[No Abstract] [Full Text] [Related]
[Next] [New Search]
